ensun logo
Locations
Company type
Result types
Industries
Employees
Founding year
Avilar Therapeutics Logo

Avilar Therapeutics

We are developing ATACs (ASGPR Targeting Chimeras), a novel class of degrader designed to harness a natural endogenous process for protein degradation. We are building an organization that is taking science to new limits and has respect for everyone. We have built a bespoke, integrated, and modular drug discovery platform to enable the design and assembly of ATACs targeting a wide array of extracellular proteins.

Quick overview

Waltham, United States

11-50 Employees

Additional information

Working industry

Biotechnology

Type of company

Manufacturer

Ownership structure

Privately Held

Locations

1 Headquarter

Number of products

1 Product

Specialised areas

Biotechnology

Products & services of Avilar Therapeutics

Avilar Therapeutics offers a wide range of products and services

Product: ATAC Platform - Avilar Therapeutics

Product

ATAC Platform - Avilar Therapeutics

Go to product >

ESG score estimation

An estimation about the ESG values based on digital data and signals. Important: The ESG scores are only based on information about the country, not the actual company itself

Country:

United States


Overall risk estimation:

Low


ESG country scores

The ESG Data of countries are based on public sources

Environment

D

Grade (A-E)

View details

Social

A

Grade (A-E)

View details

Governance

A

Grade (A-E)

View details

Headquarter of Avilar Therapeutics

Avilar Therapeutics operates in 1 country around the world

City: Waltham

State: Massachusetts

Country: United States

Locations of Avilar Therapeutics

Get an overview of the locations of Avilar Therapeutics

Location

Country

State

City

Headquarter

United States

Massachusetts

Waltham

Frequently asked questions (FAQ) about Avilar Therapeutics

Some frequent questions that have been asked about Avilar Therapeutics

The company headquarter of Avilar Therapeutics is located in Waltham, Massachusetts, United States. It's worth noting, that the company may have more locations

As of the latest available information Avilar Therapeutics has around 11-50 employees worldwide.

The company Avilar Therapeutics has it's main focus in the industries of Biotechnology

Competitors of Avilar Therapeutics

Check out some interesting alternative companies to Avilar Therapeutics

Orum Therapeutics's Logo

Orum Therapeutics

Kazan, Russia

11-50 Employees

2016

We are pioneering a class of therapeutics intended to expand the universe of druggable targets and to meaningfully improve upon potency and tolerability, and thereby improve the therapeutic window of drugs. Our goal is to bring life-changing therapies to patients by combining the power of the emerging field of protein degraders with the precision of antibodies to generate a broad portfolio of highly differentiated product candidates. A portfolio of highly differentiated products combining the power of protein degraders with the precision of antibodies.

PAQ Therapeutics's Logo

PAQ Therapeutics

Cambridge, United States

1-10 Employees

2020

We are developing a new class of small molecule degradation therapies by expanding the ability to directly target and eliminate disease-causing entities beyond proteins. PAQ’s expert team of global scientists, entrepreneurs and world-class scientific advisors are committed to broadening therapeutic horizons driven by advances in autophagy.

16250 - 1st TPD Europe 2020's Logo

16250 - 1st TPD Europe 2020

London, United Kingdom

1-10 Employees

-

As the industry consolidates pipelines and heads out of a turbulent 2023 market, the targeted protein degradation engine has shown no signs of slowing. Our blossoming community of degrader experts are inspiring each other to develop medicines to address patients’ unmet medical needs. Dedicated to Progressing the Field with Groundbreaking Research.

Aptadegrad's Logo

Aptadegrad

San Cibrao das Viñas, Spain

1-10 Employees

2022

Invest in Aptadegrad, a great opportunity to create value with rapid development of new compounds. Non-biological manufacturing of both the chemical degraders and the warheads avoids high costs and greatly reduces logistics constraints. We would be delighted to show you the advantages and benefits that Aptadegrad can provide you.

Atgc Inc's Logo

Atgc Inc

Ann Arbor, United States

1-10 Employees

2015

Our mission is to discover the best-in-class therapeutic biologics through the novel animals and technology platforms. Our mission is to discover the best-in-class therapeutics through the novel platforms. The company is dedicated to the development of novel transgenic rabbits as discovery platforms and bioreactors to produce therapeutic biologics such as monoclonal antibodies. ATGC also provides services to the biomedical community using our proprietary technology platforms and unique animals. ATGC also strives to serve the biomedical community with products and technologies using our unique platforms.

Lycia Therapeutics's Logo

Lycia Therapeutics

San Diego, United States

11-50 Employees

2019

To that end, we are advancing an undisclosed discovery pipeline of novel LYTAC degraders toward the clinic. We are also eligible to receive over $1.6 billion in potential milestone payments based on the achievement of prespecified preclinical, development and commercial milestones, as well as tiered royalties from mid-single to low double-digits on sales resulting from the agreement. We are leveraging the flexibility of our platform to pursue targets previously considered undruggable, opening the potential for new therapeutics options for patients. We are building a stellar team, driven to pioneer breakthrough science and motivated to make a difference for patients. Protein degradation offers the potential to eliminate disease-causing proteins. The mannose-6-phosphate receptor (M6PR) is a cell-surface glycoprotein that acts as a lysosomal trafficking shuttle.